Pharmacy Drugs
Recent Posts
- EMD Serono Submits Application For Cladribine Tablets As A Potential Oral Short-Course Multiple Sclerosis Therapy In The United States
- Oral Pill Fingolimod Reduces Relapses And Disability Progression
- A Potential New Imaging Agent For Early Diagnosis Of Most Serious Skin Cancer
- REMS Trigger Suit by Maker of Botulinum Toxin
- Array BioPharma To Present Clinical Results On Diabetes Drug At European Diabetes Meeting
Random Posts
- Potential New Drugs: 970 Million And Still Counting - Journal Of The American Chemical Society
- Celsion's Global Phase III ThermoDox(R) Trial Approved By State Food And Drug Administration In China
- FDA Okays Antihypertensive Combo for First-Line Therapy
- NPA Raises Profile Of Community Pharmacy At Men's Health Conference
- Merz Pharmaceuticals Announces Approval Of Post-stroke Upper Limb Spasticity Indication For Xeomin(R) In The EU
- Couples To Rely On Male Contraceptive For New Trial, UK
- Medical Care Sought In Mexico By Nearly 1 Million Californians Annually
- BYETTA Approved For Expanded Use As First-Line Treatment For Type 2 Diabetes
- NACDS Retail Advisory Board Explores Social Networking Opportunities To Engage Consumers
- Lancet Publishes 48 Week Phase III Data For 'Isentress'® (Raltegravir) In Previously Untreated (Treatment-Naïve) HIV-Infected Patients
KiobrinaTM Shows Positive Phase II Results In Preterm Infants
Posted by: admin in Pharmacy Drugs on May 17th, 2010
Biovitrum AB (STO: BVT) today announced that the first of two clinical phase II studies, designed to together show proof of concept of Kiobrina™ (rhBSSL) in preterm infants, has been completed. The results show statistically significant improvement in the growth velocity in preterm infants when Kiobrina™ was added to infant formula compared to placebo. The safety profile was comparable to that of placebo and no drug related serious adverse events were reported.
The study was a prospective randomized double-blind crossover study where Kiobrina™, or placebo, was administered in preterm infant formula during one week of treatment. All infants were born before week 32 of gestational age. The next step in the establishment of proof of concept is the completion of the second study where preterm infants are treated with Kiobrina™ administrated in pasteurized breast milk. Results from this second trial are expected in the beginning of 2010.
“The initial Phase II clinical results in this high medical need population are very encouraging. If the ongoing parallel study in preterm infants fed with pasteurized breast milk is also positive, we have proof of concept and will advance the program into a registrational stage,” said Martin Nicklasson, CEO of Biovitrum.
About Kiobrina
Kiobrina is a recombinant human bile-salt-stimulated lipase (rhBSSL) developed by Biovitrum for enzyme replacement therapy to improve growth and development in preterm infants receiving pasteurized breast milk and/or formula. The rationale for substitution of rhBSSL in pasteurized breast milk or infant formula is to restore the natural lipase activity level that is either lost on pasteurization or totally absent in formula.
Source
Biovitrum
No Comments »
No comments yet.
RSS feed for comments on this post. TrackBack URL
Leave a comment
You must be logged in to post a comment.